Drugs / RS-113
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07553988 | Oct 2024 → May 2026 overdue | prostate carcinoma | R-Pharm International, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RS-113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07553988 ↗ |
| Route | Oral | “RS-113 is taken once daily (QD) orally” NCT07553988 ↗ |